Buy Vilon Research Peptide

What is Vilon?

Vilon is a synthetic two-amino-acid peptide (Lys-Glu) from the same Russian bioregulator program as Vesugen and Epithalon. It is studied in animal research for its effects on immune signaling, particularly in thymus and bone-marrow tissue.

• A synthetic dipeptide (Lys-Glu) from the Russian organ-targeted bioregulator program
• Studied for its effects on thymus and bone-marrow immune signaling in aging models
• Animal studies have looked at immune-signaling markers and lifespan
• Studied alongside Epithalon and other bioregulators from the same program

For research use only. Not approved for human therapeutic use.

Vilon, also known by its dipeptide designation KE (Lys-Glu), is a synthetic dipeptide bioregulator with the molecular formula C11H21N3O5 and a molecular weight of 275.30 g/mol. Defined by the amino acid sequence Lys-Glu (L-Lysyl-L-Glutamic acid), Vilon is the shortest peptide in the Khavinson bioregulator series and has been identified as corresponding to the 32-33 dipeptide fragment of the 49-amino acid thymic hormone thymopoietin. Its structure pairs a basic lysine residue with an acidic glutamic acid residue. Produced via solid-phase peptide synthesis.

Vilon has been investigated in preclinical immunology as an ultra-short peptide bioregulator, with published research characterising a proposed mechanism of gene-expression modulation through direct DNA interaction rather than cell surface receptor binding. Published research examining the Lys-Glu dipeptide in human somatic cell preparations has characterised Vilon, alongside the tetrapeptide epitalon, as a proposed regulator of the expression of the ageing-associated genes CCL11 (eotaxin) and HMGB1 (alarmin), documenting these molecular markers as candidate readouts of dipeptide-mediated gene-expression modulation [1]. In vivo rodent studies have investigated the KE dipeptide in long-term ageing protocols, with published research documenting that chronic administration of the Lys-Glu dipeptide inhibited the growth of spontaneous tumours and increased life span in mice, characterising Vilon as a geroprotective agent across an extended-observation ageing protocol [2], making Vilon a key reference compound in peptide bioregulator research examining ultra-short dipeptide modulation of gene expression and gerontological endpoints in preclinical models.

Vilon is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Khavinson VK, Kuznik BI, Tarnovskaia SI, Lin’kova NS. [Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data]. Adv Gerontol. 2014;27(3):399–406. .PubMed PMID: 258269832Khavinson VK, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000;372:261–3. .PubMed PMID: 10944717

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Vilon, also known by its dipeptide designation KE (Lys-Glu), is a synthetic dipeptide bioregulator with the molecular formula C11H21N3O5 and a molecular weight of 275.30 g/mol. Defined by the amino acid sequence Lys-Glu (L-Lysyl-L-Glutamic acid), Vilon is the shortest peptide in the Khavinson bioregulator series and has been identified as corresponding to the 32-33 dipeptide fragment of the 49-amino acid thymic hormone thymopoietin. Its structure pairs a basic lysine residue with an acidic glutamic acid residue. Produced via solid-phase peptide synthesis.

Vilon has been investigated in preclinical immunology as an ultra-short peptide bioregulator, with published research characterising a proposed mechanism of gene-expression modulation through direct DNA interaction rather than cell surface receptor binding. Published research examining the Lys-Glu dipeptide in human somatic cell preparations has characterised Vilon, alongside the tetrapeptide epitalon, as a proposed regulator of the expression of the ageing-associated genes CCL11 (eotaxin) and HMGB1 (alarmin), documenting these molecular markers as candidate readouts of dipeptide-mediated gene-expression modulation [1]. In vivo rodent studies have investigated the KE dipeptide in long-term ageing protocols, with published research documenting that chronic administration of the Lys-Glu dipeptide inhibited the growth of spontaneous tumours and increased life span in mice, characterising Vilon as a geroprotective agent across an extended-observation ageing protocol [2], making Vilon a key reference compound in peptide bioregulator research examining ultra-short dipeptide modulation of gene expression and gerontological endpoints in preclinical models.

Vilon is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Khavinson VK, Kuznik BI, Tarnovskaia SI, Lin’kova NS. [Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data]. Adv Gerontol. 2014;27(3):399–406. .PubMed PMID: 258269832Khavinson VK, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000;372:261–3. .PubMed PMID: 10944717

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number64604-19-9Molecular Weight275.30 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUVIL

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Vilon, also known by its dipeptide designation KE (Lys-Glu), is a synthetic dipeptide bioregulator with the molecular formula C11H21N3O5 and a molecular weight of 275.30 g/mol. Defined by the amino acid sequence Lys-Glu (L-Lysyl-L-Glutamic acid), Vilon is the shortest peptide in the Khavinson bioregulator series and has been identified as corresponding to the 32-33 dipeptide fragment of the 49-amino acid thymic hormone thymopoietin. Its structure pairs a basic lysine residue with an acidic glutamic acid residue. Produced via solid-phase peptide synthesis.

Vilon has been investigated in preclinical immunology as an ultra-short peptide bioregulator, with published research characterising a proposed mechanism of gene-expression modulation through direct DNA interaction rather than cell surface receptor binding. Published research examining the Lys-Glu dipeptide in human somatic cell preparations has characterised Vilon, alongside the tetrapeptide epitalon, as a proposed regulator of the expression of the ageing-associated genes CCL11 (eotaxin) and HMGB1 (alarmin), documenting these molecular markers as candidate readouts of dipeptide-mediated gene-expression modulation [1]. In vivo rodent studies have investigated the KE dipeptide in long-term ageing protocols, with published research documenting that chronic administration of the Lys-Glu dipeptide inhibited the growth of spontaneous tumours and increased life span in mice, characterising Vilon as a geroprotective agent across an extended-observation ageing protocol [2], making Vilon a key reference compound in peptide bioregulator research examining ultra-short dipeptide modulation of gene expression and gerontological endpoints in preclinical models.

Vilon is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Khavinson VK, Kuznik BI, Tarnovskaia SI, Lin’kova NS. [Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data]. Adv Gerontol. 2014;27(3):399–406. .PubMed PMID: 258269832Khavinson VK, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000;372:261–3. .PubMed PMID: 10944717

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number64604-19-9Molecular Weight275.30 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUVIL

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.